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Abstract: BACKGROUND: The prevalence of chronic kidney disease (CKD) is increasing worldwide
in part due to population ageing. Identifying risk factors for age-related kidney function decline could
help in understanding mechanisms for kidney ageing. Sodium and potassium intakes are associated with
CKD progression in the renal population, but little is known on their role in renal function decline [mean
estimated glomerular filtration rate variation (ΔeGFR)] in the general adult population. METHOD:
We therefore explored the association of urinary sodium and potassium excretions with ΔeGFR in a
longitudinal population-based cohort. We estimated 24-h urinary sodium (eUNa), potassium (eUK)
and sodium-to-potassium ratio (eUNa/K) from spot urine using Kawasaki formulae. We performed
multivariate linear regression models studying the association of eUNa, eUK and eUNa/K with yearly
ΔeGFR, taking several covariates into account, including baseline eGFR and albuminuria. RESULTS:
There were 4141 white participants from which 54.3% were women. Median age was 51.5 [43.6-60.6] years
and mean baseline eGFR 88 (SD 15) ml/min per 1.73 m. During a median follow-up of 5.4 years, mean
ΔeGFR was -0.59 (SD 1.68) ml/min per 1.73 m per year. In the fully adjusted model, high eUNa and
eUNa/K were associated with faster renal function decline with standardized coefficients ฀ = -0.07 (95%
confidence interval: -0.11 to -0.04) and ฀ = -0.05 (95% confidence interval: -0.08 to -0.02), respectively. By
contrast, eUK, taken alone, showed no association. CONCLUSION: These results suggest that dietary
sodium and potassium intakes may play a role in kidney function decline in the general adult population.
Whether lowering sodium and increasing potassium in the diet may help in CKD prevention needs further
exploration.
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Estimated 24-h urinary sodium and sodium-to-
potassium ratio are predictors of kidney function
decline in a population-based study
Denis Deriaza, Idris Guessousa,b, Peter Vollenweiderc, Olivier Devuystd, Michel Burniere,
Murielle Bochuda,, and Belen Pontea,f,
Background: The prevalence of chronic kidney disease
(CKD) is increasing worldwide in part due to population
ageing. Identifying risk factors for age-related kidney
function decline could help in understanding mechanisms
for kidney ageing. Sodium and potassium intakes are
associated with CKD progression in the renal population,
but little is known on their role in renal function decline
[mean estimated glomerular filtration rate variation
(DeGFR)] in the general adult population.
Method: We therefore explored the association of urinary
sodium and potassium excretions with DeGFR in a
longitudinal population-based cohort. We estimated 24-h
urinary sodium (eUNa), potassium (eUK) and sodium-to-
potassium ratio (eUNa/K) from spot urine using Kawasaki
formulae. We performed multivariate linear regression
models studying the association of eUNa, eUK and eUNa/K
with yearly DeGFR, taking several covariates into account,
including baseline eGFR and albuminuria.
Results: There were 4141 white participants from which
54.3% were women. Median age was 51.5 [43.6–60.6]
years and mean baseline eGFR 88 (SD 15)ml/min per
1.73m2. During a median follow-up of 5.4 years, mean
DeGFR was 0.59 (SD 1.68)ml/min per 1.73m2 per year.
In the fully adjusted model, high eUNa and eUNa/K were
associated with faster renal function decline with
standardized coefficients b¼0.07 (95% confidence
interval: 0.11 to 0.04) and b¼0.05 (95% confidence
interval: 0.08 to 0.02), respectively. By contrast, eUK,
taken alone, showed no association.
Conclusion: These results suggest that dietary sodium and
potassium intakes may play a role in kidney function
decline in the general adult population. Whether lowering
sodium and increasing potassium in the diet may help in
CKD prevention needs further exploration.
Keywords: renal function decline, salt, sodium, urinary
sodium-to-potassium ratio
Abbreviations: 25D, 25-hydroxyvitamin D; ACR, albumin-
to-creatinine ratio; CKD, chronic kidney disease; CoLaus,
Cohort Lausanne study; DASH, Dietary Approaches to Stop
Hypertension; eGFR, estimated glomerular filtration rate;
eUK, estimated 24-h urinary potassium excretion; eUNa/K,
eUNa divided by eUK; eUNa, estimated 24-h urinary
sodium excretion; Na/K ratio, sodium-to-potassium ratio;
NHANES, The National Health and Nutrition Examination
Survey; PREVEND, The Prevention of Renal and Vascular
End-Stage Disease study; UCr, urinary concentration of
creatinine; UNa, urinary concentration of sodium; DeGFR,
mean estimated glomerular filtration rate variation
INTRODUCTION
H
igh-sodium intake and low-potassium intake are
known dietary risk factors for arterial hypertension
(AH) [1–3]. High-potassium intake reduces blood
pressure (BP) and the risk of stroke [4]. Data regarding their
role in cardiovascular morbidity and mortality are more
controversial. In the US The National Health and Nutrition
Examination Survey (NHANES) study, sodium intake and
sodium-to-potassium intake ratio estimated by 24-h dietary
recalls were associated with higher all-cause and cardio-
vascular mortality, whereas potassium intake appeared to
be protective, with the strongest predictive value for the
sodium-to-potassium intake ratio [5]. In the Prospective
Urban Rural Epidemiology study, a large worldwide study,
similar results were obtained using the Kawasaki formula to
estimate 24-h urinary sodium and potassium excretions [3].
A similar association with cardiovascular events was found
by using sodium-to-potassium excretion ratio in 24-h urine
[6]. On the contrary, some studies rather showed an
increase in mortality with lower sodium intake either at
population or more recently at a community level [7,8].
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A few observational studies explored the association of
sodium intake with renal outcomes either by using 24-h
urinary sodium excretion [9–13] or dietary recalls [14–16].
In most of them, high-sodium intake was associated with a
higher risk of kidney function decline [15] and a more rapid
progression to chronic kidney disease (CKD) [9], although
an inverse association was found cross-sectionally in the
NHANES study [16] and no association was found in the
Prevention of Renal and Vascular End-Stage Disease (PRE-
VEND) study [13]. A high-sodium intake can have an effect
on kidney function through direct long-term BP effect on
vessels, thereby accelerating arteriolosclerosis. High
sodium and high BP can both induce hyperfiltration and
glomerular damage in the long term. Other potential mech-
anisms are by modulating intra-renal transforming growth
factor (TGF)-b1 production, a fibrinogenic factor partici-
pating in CKD progression [17], and/or by inducing adeno-
sine-related vasoconstriction in the macula densa.
Potassium intake seems to have a protective effect on
renal outcomes [9,11–13,16,18–20]. Most observational
studies analysed 24-h urinary potassium excretion
[9,11,12,19], one looked at serum potassium [18] and two
considered self-reported diet [16,20]. Recently, the PRE-
VEND study reported that a low 24-h urinary potassium
excretion was rather associated with increased 10-year
risk of CKD [13]. The mechanisms underlying the
protective role of potassium on renal function are not clear,
but could be related to decreased vascular stiffness and
nitric oxide release and reduced BP sensitivity to sodium
intake [21,22].
A high urinary sodium-to-potassium ratio (Na/K ratio)
jointly captures both high-sodium intake and low-potas-
sium intake [23] and should therefore allow to identify a
complex set of unhealthy dietary patterns, such as a diet
rich in salty products and poor in fruits and vegetables. The
practical usefulness of urinary Na/K ratio for human studies
is further enhanced by the availability of self-monitoring
devices [24], by the facts that the ratio is less dependent on
the urine collection or creatinine measurement and that the
spot ratio better correlates to the 24-h ratio than sodium or
potassium taken individually [25]. Sodium-to-potassium
intake ratio may represent a better dietary biomarker to
capture cardiorenal risk than either sodium or potassium
intakes alone [23]. Jointly considering sodium and potas-
sium intakes appears to be particularly relevant for the
kidney-related pathogenesis of AH [26].
We explored the association of urinary sodium and
potassium excretions as well as urinary Na/K ratio, derived
from morning spot urine, with age-related kidney function
decline in a population-based cohort [Cohort Lausanne
study (CoLaus)]. We hypothesized that high urinary sodium
and Na/K ratio would be predictive of a faster age-related
kidney function decline and that high urinary potassium
would rather be protective.
METHODS
The Cohort Lausanne study
One of the main goals of the CoLaus study was to determine
the prevalence of cardiovascular risk factors and diseases in
the general population. CoLaus is a longitudinal cohort
study including a general population-based sample from
the city of Lausanne in Switzerland. The baseline examina-
tion started in 2003–2006 with the first follow-up on aver-
age 5-year later (2009–2012). The complete sample method
has already been described [27]. Briefly, a simple randomi-
zation from the city of Lausanne’s register selected 19 830
people, representing 35% of the registered population, who
were then contacted by post. Inclusion criteria were written
informed consent; aged from 35 to 75 years old; white
origin. They were 6184 people responding to the inclusion
criteria and who completed the baseline investigation, then
76% (n¼ 4679) of these also completed the follow-up. The
study respects the Declaration of Helsinki and was
approved by the Ethics Committee of the Canton of Vaud.
Biological and clinical data
The participants came to the University Hospital from
Lausanne for a clinical examination, after an overnight fast.
BMI was defined as weight/height in kg/m2. Waist circum-
ference was measured following standardized recommen-
dations [27]. Participants remained at rest in a seated
position for at least 10min and BP was measured three
times using an Omron-automated oscillometric sphygmo-
manometer. The average of the last two measurements was
used for analyses.
Venous blood samples were drawn during the clinical
examination. During the same visit, one single spot urine
sample was obtained from the second voiding urine speci-
men in the morning. All samples (blood and urine) were
taken in the morning while the participants were still
fasting. Venous blood glucose, lipid profile and renal
function tests as well as urinary electrolytes were analysed
by standard clinical methods. Serum 25-hydroxyvitamin D
(25D) was measured centrally by an ultra-high-pressure
liquid chromatography-tandem mass spectrometry system.
Month-specific tertiles were calculated for serum 25D
because of seasonal concentration variations. Ultrasensitive
C-reactive protein (CRP) was measured by immunoassay
and high-sensitivity latex assay. Serum and urinary creati-
nine was measured using the Jaffe isotope dilution mass
spectrometry (IDMS) traceable measurement kinetic com-
pensated method (Roche Diagnostics, Switzerland; coeffi-
cient of variation (CV) 2.9–0.7%). Albuminuria was
measured using a bromocresol green assay (Roche Diag-
nostics, Switzerland; CV 2.5–0.4%) and was expressed in
mg/dl. Albumin-to-creatinine ratio (ACR) was calculated as
the ratio of albumin over creatinine in mg/g. Urinary
sodium and potassium were determined by indirect poten-
tiometry (UniCEl DxC 800 Synchron System; Beckman
Coulter, Brea, California, USA).
Participants had to complete a questionnaire about their
socioeconomic status, cardiovascular risk factors and cur-
rent medication. The level of education was classified as
‘low’, ‘middle’ or ‘high’. Participants were considered phys-
ically ‘active’ if they completed at least 20min of physical
activity once per week. They were considered ‘smokers’
only if they were active smokers. Diabetes was defined as
presence of current – or previous – antidiabetic treatment
or a fasting glycemic value greater than 7mmol/l. Hyper-
tension medication was reported by the patient.
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Estimated glomerular filtration rate
Estimated glomerular filtration rate (eGFR) was calculated
from the baseline and 5-year follow-up serum creatinine
using the Chronic Kidney Disease - Epidemiology Collabo-
ration (CKD-EPI) equation [28]. Then, annual mean CKD-
EPI variation [mean eGFR variation (DeGFR)] used two
creatinine values, and was defined as:
DeGFR ¼
CKD-EPI follow u p  CKD-EPIbaseline
 




Estimated 24-h urinary sodium excretion and
estimated 24-h urinary potassium excretion
We estimated 24-h urinary sodium and potassium excre-
tions from concentrations of these electrolytes in the base-
line urine sample using the Kawasaki formulae [29]:






















In these equations, eUNa and eUK are the estimated 24-h
sodium and potassium excretion in mg and in which UNa
and UK are the urinary concentrations of sodium and
potassium in mmol/l, respectively. To compare with inter-
national recommendations, and most of the previous stud-
ies, we transformed sodium and potassium frommmol/24 h
to mg/24 h by using their molecular weight: 22.9 and
39.10, respectively.
UCr is the urinary concentration of creatinine in mg/dl in
the urine sample and eUCr is the estimated 24-h urinary
creatinine excretion in mg calculated as followed:
eUCr ¼ 12:63 ageþ 15:12weightþ 7:39
 height 79:9 for men; and
eUCr ¼ 4:72 ageþ 8:58weightþ 5:09
 height 74:5 for women:
As eUNa/K can be directly defined as a function of UNa/
UK measured in the sample after algebraic simplification
(removing imprecision of the estimation of 24-h creatinine),
our results apply also to measured UNa/UK where eUNa/
K¼C square root (UNa/UK) when C¼ 1.67 for men. As
expected, correlation between eUNa/K and measured
UNa/UK was 1.0 (Spearman’s correlation).
Descriptive statistics
Participants who lacked any of the baseline covariates or
variables of interest (n¼ 703) or values at follow-up
(n¼ 1342) were excluded from all statistical analyses that
finally included 4141 participants. Distribution of continu-
ous variables was graphically checked. To avoid extreme
outliers, we decided to winsorize values of BMI, UCr, eUNa,
eUK, urinary albumin and eGFR at percentiles 1 and 99%.
Continuous variables were expressed in means and
SDs except if the distribution was skewed, in which case
variables were accordingly expressed in medians and
interquartile ranges (IQR: 25th and 75th percentiles). Cate-
gorical variables were expressed in proportions. Continu-
ous variables and categorical variables were compared by
sex using the t test – or the median test if the distribution
was skewed – and the x2 test for independence,
respectively.
Association analyses
We graphically checked the distribution of the previously
cited continuous variables and transformed some which
were skewed: UCr was square-root transformed, ACR
inversely square-root transformed and ultrasensitive CRP
log transformed.
First, we performed univariate linear regressions describ-
ing DeGFR as a function of age, sex, physical activity,
smoking status, diabetes, antihypertensive medication,
BMI, SBP, DBP, mean arterial BP (MAP), triglycerides, total
cholesterol, uric acid, ultrasensitive CRP, 25D, 25D months
tertiles, baseline eGFR, ACR, and eUNa, eUK or eUNa/K,
separately. Variables with P value 0.10 or less in univariate
linear regressions were considered as significant and were
chosen as covariates in multivariate linear regressions mod-
els as well as variables known to be associated in the
literature with eGFR decline. We forced age and sex into
the models. Other significant covariables were: physical
activity, smoking status, diabetes, antihypertensive medi-
cation, SBP, BMI, triglycerides, uric acid, ultrasensitive CRP,
25D, ACR and baseline eGFR. eUNa and eUK or eUNa/K
were the variables of interest. We chose SBP rather than
MAP because of a greater adjusted R-squared value and a
greater standardized coefficient of the absolute value. For
the same reason, we chose 25D instead of month-specific
terciles of the vitamin.
Then we generated three different multivariate linear
regression models defining DeGFR (i.e. the outcome).
Model 1 described DeGFR as a function of eUNa and
eUK – or eUNa/K – adjusting for age and sex. Model 2
was adjusted for all previously described significant
variables and ACR. Model 3 was similar to Model 2
but not adjusted for ACR. Models 1, 2 and 3 were either
adjusted for baseline eGFR or not. Results are presented
with the standardized regression coefficients (b), calcu-
lated from standardized continuous variables (both
dependant and independent), that is [variable Xmean
variable X]/SD of X, their 95% confidence intervals and the
P value of the variable of interest in the model from the
Wald test.
Interactions between eUNa, eUK and eUNa/K with sex,
age and hypertension status were tested by adding the
interaction factor into Model 2: e.g hypertensioneUNa.
An interaction with a P value 0.10 or less was considered as
significant. There were no significant interactions with sex,
age or hypertension. We also tested interaction with hyper-
tension status using eUNa, eUK and eUNa/K quintiles
groups. We performed a likehood ratio test (LRT) to com-
pare models with the interaction factor to the model with-
out it, considering eUNa, eUK and eUNaK in quintiles
groups instead of continuous variables: e.g hyperten-
sioneUNa_quintiles. LRT P values were more than 0.1
for all.
Sodium, potassium, estimated glomerular filtration rate decline
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To test the linearity as a condition for using linear regres-
sions, we calculated DeGFR by quintiles of eUNa, eUK and
eUNa/K andwe calculatedP for the trend for these variables.
Linearity was present with all P values less than 0.10.
Main statistical analyses were performed using Stata 14.0
(StataCorp, College Station, Texas, USA).
RESULTS
We included 4141 participants without missing data and
with a median follow-up of 5.4 (IQR: 5.3–5.6) years. Their
characteristics by sex are shown in Table 1. There were
54.3% women. For the whole population, the median age
was 51.5 (IQR: 43.6–60.6) years and mean baseline eGFR
85.7 (SD 14.8)ml/min per 1.73m2. Table 1 reported the
mean eGFR (SD) by sex; the median eGFR [IQR] was 88.4
[77.7–98.6] and 83.9 [74.2–94.5]ml/min per 1.73m2 in men
and women, respectively. The total mean eGFR decline in
ml/min per 1.73m2 per year was 0.59 (SD 1.68) and the
median 0.61 (IQR: 1.58–0.45). Men had higher preva-
lence of cardiovascular risk factors such as smoking, dia-
betes, antihypertensive medication, higher BMI, SBP, DBP,
triglycerides and uric acid. eGFR at baseline was higher in
men than in women but men showed a greater decline over
time than women. Men had higher eUNa, eUK and eUNa/K
than women. Women were older, had higher levels of
vitamin D, higher CRP and albuminuria levels.
In Fig. 1 (as well as Supplementary Table S1, http://
links.lww.com/HJH/B89), we depicted unadjusted DeGFR
by quintiles of eUNa, eUK and eUNa/K. This result shows
an increase in eGFR decline with a significant trend across
higher quintiles for the three variables of interest.
Association analyses
In univariate linear regressions, eUNa, eUK and eUNa/K
were significantly associated with the decline in renal
function, higher urinary levels of all parameters being
associated with a steeper decrease in renal function.
The multivariate linear regression models are presented
in Table 2 adjusted or not for baseline eGFR. Models
adjusted for baseline eGFR had a better predictive value
when considering R-squared values. The addition of micro-
albuminuria had little impact on the coefficients. As shown
in Table 2, we observed significant inverse association
(¼negative b-coefficients) for eUNa in both nonadjusted
and adjustedmodels for baseline eGFR. To illustrate the size
of the effect, an increment of 1 g of eUNa accelerates on
average the kidney function decline by 0.1ml/min per
1.73m2 per year whenever adjusting for baseline eGFR.
eUNa/K showed also significant negative b-coefficients in
all models, meaning an inverse association with eGFR
decline. Although eUK was also negatively associated with
renal function decline in models not accounting for base-
line eGFR, further adjustment for baseline eGFR changed
the direction of the association, which became NS.
We did not found any interaction between age, sex or
hypertension status and eUNa, eUK or eUNaK in our cohort
neither using continuous nor categorical variables.
Sensitive analyses
We found similar results when we repeated the analyses
after removing extreme outliers instead of winsorizing (p1,
p99) variables.
To estimate the impact of a ‘loss to follow-up bias’, we
compared characteristics between people included in the
follow-up and those lost to follow-up (Supplementary
Table S2, http://links.lww.com/HJH/B89). People included
in the follow-up were younger and were healthier than
people lost to follow-up: more physically active, less smok-
ers, less diabetes, less antihypertensive treatment, lower
BMI, lower SBP/DBP, lower triglycerides, lower uric acid,
lower CRP, lower ACR and higher vitamin D values. There
TABLE 1. Participants’ characteristics by sex (participants included in the follow-up, n¼4141)
Variable Men, n¼1891 (45.7%) Women, n¼2250 (54.3%) P value
Age (years) 50.4 [42.8–60.0] 52.5 [44.3–61.3] <0.001
Physically active, n (%) 1259 (67%) 1522 (68%) 0.47
Active smoking, n (%) 516 (27%) 550 (24%) 0.037
Diabetes, n (%) 157 (8.3%) 72 (3.2%) <0.001
Antihypertensive medication, n (%) 343 (18.1%) 303 (13.5%) <0.001
BMI (kg/m2) 26.43.8 24.84.6 <0.001
Waist (cm) 95.210.9 82.512.1 <0.001
SBP (mmHg) 131.316.3 123.617.6 <0.001
DBP (mmHg) 81.110.7 76.910.4 <0.001
MAP (mmHg) 97.911.8 95.511.9 <0.001
Serum cholesterol (mmol/l) 5.591.03 5.601.00 0.96
Serum triglycerides (mmol/l) 1.3 [0.9–1.9] 1.0 [0.7–1.3] <0.001
Serum uric acid (mg/dl) 36074 26866 <0.001
Serum 25-hydroxyvitamin D (ng/ml) 47.121.9 49.222.2 0.003
hsCRP (mg/l) 1.1 [0.6–2.3] 1.2 [0.6–2.8] 0.024
eGFR (ml/min per 1.73m2) 87.714.7 84.014.6 <0.001
DeGFR (ml/min per 1.73m2 per year) 0.671.64 0.521.71 0.007
ACR (mg/g) 4.3 [3.0–7.5] 5.5 [3.7–9.2] <0.001
eUNa (mg/24 h) 42621202 35021095 <0.001
eUK (mg/24 h) 2557543 2246486 <0.001
eUNa/K 1.710.51 1.590.50 <0.001
Continuous variables are expressed as the mean SD or median and IQR [25–75th percentiles] as appropriate. Categorical variables are expressed in numbers and percentages. ACR,
urinary albumin-to-creatinine ratio; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate using the CKD-Epidemiology Collaboration (CKD-EPI) equation; eUNa and
eUK, estimated 24-h excretion of sodium and potassium, respectively; eUNa/K, ratio of eUNa to eUK; hsCRP, ultrasensitive C-reactive protein; MAP, mean arterial blood pressure.
Deriaz et al.
1856 www.jhypertension.com Volume 37  Number 9  September 2019
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
was no significant difference in baseline eGFR UNa, urinary
concentration of potassium or UCr between these two
groups. People included in follow-up had lower eUNa
(and eUNa/K) than people lost to follow-up.
DISCUSSION
In this study, we found that high urinary sodium excretion
and high urinary sodium-to-potassium excretion ratio were
associated with a faster kidney function decline in adults
from the general adult population, independently of major
potential confounders such as baseline eGFR and albumin-
uria and BP. We could not find a significant protective or
deleterious effect of urinary potassium excretion when
accounting for baseline renal function. These results high-
light the importance of dietary factors in kidney function
decline and hence CKD prevention at a population level.
In some but not all observational studies, sodium intake,
using 24-h urinary sodium excretion, has been associated
with renal function decline and increased risk of CKD
[15,18]. An increased risk of adverse cardiovascular out-
come is also reported in patients with CKD when sodium
intake is more than 4 g of sodium per day [9,30], although it
seems to be a J-shape curve association in the general
population [13]. Moreover, there are limited experimental
data studying the effect of lowering sodium intake on renal
disease progression [31–34]. A hypothesis for the beneficial
effect of lowering sodium intake is that, in combination
with a low-protein diet and angiotensin-modulation ther-
apy, there is a more pronounced decrease in intraglomer-
ular pressure and proteinuria which could slow kidney
disease progression [35–38]. In experimental models,
sodium intake increases TGF-b production and reactive
oxygen species [39,40]. In addition to these effects, inde-
pendent of BP, the adverse effect of sodium intake on
vessels and hypertension could also explain the association
with kidney disease progression [41,42].
We did not find any association between potassium
excretion and renal function once adjusting for baseline
renal function. Epidemiological studies have shown a pro-
tective effect of potassium intake on mortality and CV






















































































FIGURE 1 Yearly change in estimated glomerular filtration rate in ml/min per 1.73m2
per year (a) by quintiles of estimated 24-h excretion of sodium in mg/day (blue squares)
and potassium in mg/day (red triangles); (b) by quintiles of estimated 24-h excretion
sodium-to-potassium ratio (n¼4141). Vertical bars correspond to the standard errors
of the mean. eGFR, estimated glomerular filtration rate; eUNa and eUK, estimated
24-h excretion of sodium and potassium, respectively; eUNa/K, ratio of eUNa to eUK.
TABLE 2. Multivariate regression analysis of estimated 24h urinary excretion of sodium potassium and sodium-to-potassium ratio with
the yearly change in estimated glomerular filtration rate (ml/min per 1.73m2 per year) (n¼4141)
Not adjusted for baseline eGFR Adjusted for baseline eGFR
b P value 95% CI b P value 95% CI
Model 1
eUNa 0.12 <0.001 0.16 to 0.09 0.07 <0.001 0.11 to –0.04
eUK 0.03 0.17 0.06 to 0.01 0.03 0.33 0.01–0.06
eUNa/K 0.07 <0.001 0.10 to 0.04 0.06 <0.001 0.08 to 0.03
Model 2
eUNa 0.11 <0.001 0.14 to 0.07 0.07 <0.001 0.11 to 0.04
eUK 0.05 0.008 0.08 to 0.01 0.02 0.30 0.02–0.05
eUNa/K 0.06 <0.001 0.09 to 0.02 0.05 <0.001 0.08 to 0.02
Model 3
eUNa 0.11 <0.001 0.14 to 0.07 0.07 <0.001 0.11 to 0.04
eUK 0.05 0.010 0.08 to 0.01 0.02 0.28 0.01–0.05
eUNa/K 0.05 0.001 0.08 to 0.02 0.05 <0.001 0.08 to 0.02
b-Coefficient of the regression line for each increase in 1SD of continuous dependent and independant variables. eUNa and eUK are the estimated 24-h excretion of sodium and
potassium respectively in mg/day. Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, physical activity, smoking status, diabetes, antihypertensive medication, SBP, BMI,
triglycerides, uric acid, CRP, 25-hydroxyvitamin D and ACR. Model 3: Model 2 without ACR as a covariate. ACR, albumin-to-creatinine ratio; CI, confidence interval; CRP, C-reactive
protein; eGFR, estimated glomerular filtration rate; eUK, estimated 24-h urinary potassium excretion; eUNa, estimated 24-h urinary sodium excretion; eUNa/K, ratio of eUNa to eUK.
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disease [12,19,43]. The probable different effects of sodium
and potassium on kidney function decline can be explained
by their opposite cellular effects involving, for example,
opposite action on nitric oxide release. Potassium also
seems to have a direct effect on sodium excretion in animals
by controlling the phosphorylation of sodium-chloride
symporter [5,44]. However, data are conflicting: a recent
study found higher potassium intake to be associated with
kidney disease progression in CKD patients and another
one described a higher risk of developing CKD with low
potassium [15,19]. Despite these conflicting results, the
WHO has reiterated the recommendation of reducing
sodium intake and increasing potassium intake [43].
We have shown that a higher Na/K ratio was associated
with a steeper decline in renal function. We only have
found one study in a general population from Japan ana-
lysing longitudinally Na/K ratio as a predictor of renal
function [45]. Similar to our study, the authors described
that higher baseline ratio was associated with greater eGFR
decline. However, their analyses mainly focused on BP.
Even the PREVEND study, a population-based study with-
out CKD, had not looked at the urinary ratio [19]. A higher
ratio may reflect a higher sodium intake, a lower potassium
intake or both. The Na/K ratio is robust to errors related to
incomplete collections and is independent of creatinine
measurements [23]. Na/K ratio has been studied in relation
to BP and mortality and higher ratios were associated with a
higher BP and higher risk of hypertension in the general
population and were predictive of worse outcomes [46,47].
The estimated reduction was even larger when using the
ratio compared with sodium and potassium excretions
separately. More recent studies also confirm these results
[5,48,49]. A recent study looked at the effects of the Dietary
Approaches to Stop Hypertension (DASH) diet – thus
consequently with a lower Na/K ratio – on CKD incidence.
In this study, volunteers in the highest tertile of DASH score
(DASH-style diet) were 16% less likely to develop CKD
comparing with those in the lowest tertile DASH score [50].
Our study has several strengths. First, it has an optimal
design, being observational and population-based with a
long period between baseline and follow-up investigations.
Second, we used Kawasaki formulae to estimate 24-h
excretions of sodium and potassium – which are more
precise than simple urine sample concentrations – as a
marker of sodium and potassium intakes. Third, we also
adjusted models for baseline eGFR and for several risk
factors for renal function decline.
There are, however, some limitations. We measured
urinary sodium and potassium in a single spot urine sample
at baseline. Thus, we neglected individual variations in
excretion of these electrolytes related to circadian rhythms
and dietary variations. Moreover, we used Kawasaki for-
mulae which did not seem tomatch exactly with 24-h urines
in a recent study [51]. On the other hand, the use of Na/K
ratio overcomes the problem of the sample variability and
the lack of precision from formulae used to extrapolate 24-h
excretion. Moreover, the correlation between spot and 24-h
urine was better for Na/K ratio than for sodium or potas-
sium, taken alone [25]. Residual confounding is still possi-
ble. Finally, regarding the outcome, we estimated the
decline using two creatinine measures at a 5-year interval.
With such two time-points data, we assumed linearity of the
renal function decline and did not account for variability in
the creatinine values. A recent article suggested that in most
cases assuming linearity of renal function decline is correct
[52]. Of course, with only two measures, we cannot exclude
that we had overestimated or underestimated the decline in
eGFR, by including participants with acute renal disease at
baseline or follow-up.
In conclusion, we observed a significant linear associa-
tion between urinary sodium excretion and age-related
kidney function decline. We found no significant associa-
tion between urinary potassium excretion and age-related
kidney function decline when taking into account baseline
renal function. Na/K ratio was also a predictor of age-
related kidney function decline but essentially driven by
the sodium component of the ratio as it was less predictive
than sodium alone. Our results suggest that reducing
sodium intake and having a low-dietary Na/K ratio may
slow down the progression to CKD. However, whether a
lower Na/K ratio should be obtained by reducing sodium
intake only, both reducing sodium and increasing potas-
sium intakes or increasing potassium intake alone is not
known. This may well depend on the level of eGFR at
which the intervention is introduced. In addition, whether
nutritional interventions, such as low-sodium and high-
potassium diet, may help preventing CKD needs further
exploration.
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